The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series
- PMID: 24440159
- DOI: 10.1016/j.ypmed.2014.01.007
The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series
Abstract
Objective: Economic incentives can positively influence social determinants to improve the health care of the uninsured and underserved populations. The aim of this study was to determine if free HPV4 vaccine would lead to on-time series completion in our safety net health care system in the US Midwest.
Methods: A nested retrospective cohort study of females receiving HPV4 vaccine between 2006 and 2009 was conducted. Patient characteristics and payor source for each of the three HPV4 doses were abstracted from electronic records. Logistic regression was used to predict on-time completion rates.
Results: The proportion of adolescent and adult females completing three on-time HPV4 doses was equal (21% (28/136) vs. 18% (66/358), respectively) from among the 494 females receiving 927 HPV4 doses in this study. No adolescent receiving free HPV4 vaccine completed three doses. Grant sponsorship of at least one HPV4 dose among adults did not predict three dose on-time completion (OR=1.56, 95%CI: 0.80, 3.06). Neither was adult grant sponsorship of HPV4 significant when analyzing exclusive payor sources vs. a combination of payor sources (OR=0.72, 95%CI: 0.10, 5.17).
Conclusions: Free HPV4 vaccine does not influence the on-time completion rates among adults.
Keywords: Compliance; Economic incentive; HPV4 vaccine; Health insurance; Payor source.
Copyright © 2014 Elsevier Inc. All rights reserved.
Comment in
-
Philanthropic support of HPV vaccination efforts.Prev Med. 2015 Jul;76:126. doi: 10.1016/j.ypmed.2014.11.032. Epub 2015 Feb 3. Prev Med. 2015. PMID: 25657169 No abstract available.
-
Response to philanthropic support of HPV vaccination efforts.Prev Med. 2015 Jul;76:127-8. doi: 10.1016/j.ypmed.2014.12.042. Epub 2015 Feb 2. Prev Med. 2015. PMID: 25657170 No abstract available.
Similar articles
-
Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.PLoS One. 2013 Aug 8;8(8):e71295. doi: 10.1371/journal.pone.0071295. eCollection 2013. PLoS One. 2013. PMID: 23951123 Free PMC article.
-
Factors predicting completion of the human papillomavirus vaccine series.J Adolesc Health. 2013 Apr;52(4):427-32. doi: 10.1016/j.jadohealth.2012.09.009. Epub 2012 Dec 10. J Adolesc Health. 2013. PMID: 23298984
-
Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates.PLoS One. 2014 May 9;9(5):e96277. doi: 10.1371/journal.pone.0096277. eCollection 2014. PLoS One. 2014. PMID: 24816199 Free PMC article.
-
Quantifying clinical HPV4 dose inefficiencies in a safety net population.PLoS One. 2013 Nov 6;8(11):e77961. doi: 10.1371/journal.pone.0077961. eCollection 2013. PLoS One. 2013. PMID: 24223131 Free PMC article.
-
Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.Cancer. 2008 Nov 15;113(10 Suppl):3004-12. doi: 10.1002/cncr.23765. Cancer. 2008. PMID: 18980296 Review.
Cited by
-
Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students.Papillomavirus Res. 2018 Jun;5:114-121. doi: 10.1016/j.pvr.2018.03.007. Epub 2018 Mar 23. Papillomavirus Res. 2018. PMID: 29578098 Free PMC article.
-
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Hum Vaccin Immunother. 2015;11(7):1689-702. doi: 10.1080/21645515.2015.1050570. Hum Vaccin Immunother. 2015. PMID: 26062002 Free PMC article. Clinical Trial.
-
HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US.Hum Vaccin Immunother. 2023 Dec 31;19(1):2161253. doi: 10.1080/21645515.2022.2161253. Epub 2023 Jan 11. Hum Vaccin Immunother. 2023. PMID: 36631995 Free PMC article.
-
HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.Papillomavirus Res. 2016 Dec;2:1-8. doi: 10.1016/j.pvr.2015.10.001. Papillomavirus Res. 2016. PMID: 26623444 Free PMC article.
-
Behavioral interventions for vaccination uptake: A systematic review and meta-analysis.Health Policy. 2023 Nov;137:104894. doi: 10.1016/j.healthpol.2023.104894. Epub 2023 Sep 4. Health Policy. 2023. PMID: 37714082 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources